Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bihormonal iLet Bionic Pancreas Feasibility Study
NCT03840278Phase 3Completed
- Sponsor
- Massachusetts General Hospital
- Start
- May 2019
- Primary completion
- Jul 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dasiglucagon in type 1 diabetes mellitus (T1D), sponsored by Massachusetts General Hospital. Started May 2019; status: completed.
02
Drugs
dasiglucagon
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03840278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03840278.